Recombinant adeno-associated virus vectors based on serotype 2 (rAAV2) have been used to deliver transgenes to the airways in a variety of pre-clinical and clinical studies. Gene transfer in these studies has been severely restricted by the basolateral localization of rAAV2 receptors. Here, we studied vectors constructed from the AAV5 genome and capsid, which utilize N-linked sialic acid-containing receptors found on the apical surface of airway epithelial cells. We investigated gene transfer efficacy and duration of transgene expression following delivery of rAAV5/5 vectors to the mouse respiratory tract. Robust, dose-dependent transgene expression was observed in the epithelium lining the nose for at least 32 weeks, and for at least 52 weeks in the lung. Importantly, in the lung, transgene expression mediated by rAAV5/5 was 40-fold greater than by rAAV2/2 vectors. A distinct cellular preference for rAAV5/5-mediated transduction was observed, with transgene expression being predominantly restricted to sustentacular cells of the olfactory epithelium in the nose and alveolar type II cells in the lung. Administration of rAAV5/5 vectors to both the nose and lungs led to the rapid development of rAAV5/5-neutralizing antibodies, suggesting that repeated administration may be severely hampered by host immune responses.
Introduction
Recombinant adeno-associated virus (rAAV) vectors have been studied in a range of tissues including muscle, 1 lungs, 2 liver, 3 brain 4 and retina. 5, 6 Disease models in which clinically relevant levels of transgene expression were obtained with rAAV vectors include hemophilia B mice treated with Factor IX-expressing virus 7 and alpha-1 antitrypsin (AAT) deficiency. 8 The popularity of rAAV vectors is due in part to the fact that wild-type AAV is non-pathogenic in humans and relatively non-immunogenic. 9 Many of the investigations using rAAV have concentrated on serotype 2 (rAAV2), which demonstrates a wide tissue tropism and persistent gene expression in various animal species. As a result, several clinical trials involving rAAV2 vectors have been initiated, most notably involving patients with cystic fibrosis (CF) [10] [11] [12] and hemophilia. 13 Studies using vectors pseudotyped with the capsid proteins of other known serotypes (e.g. rAAV2/1, rAAV2/4, rAAV2/5) have further underlined the versatility of rAAV vectors, with divergent capsids affecting the efficiency of transduction in a variety of organs. For example, rAAV2/5 transduces skeletal and smooth muscle at higher efficiency than rAAV2/2.
14 Similarly, transduction levels and cellular tropism of rAAV2 pseudotyped with serotype 2, 4 or 5 were significantly different following intracerebral injection, which may have important implications for the application of such vectors in various disease models. 4 Others have demonstrated that different pseudotypes of rAAV transduce different cell types in the retina, with variable levels of efficiency, probably based on different entry mechanisms into target cells. 5, 6 Furthermore, the list of available AAV serotypes continues to grow, suggesting there is great potential for further refinement of rAAV vectors. 15, 16 We are interested in using rAAV vectors for lung gene transfer. The lungs are an attractive target because they are accessible via minimally invasive techniques such as nebulization and bronchoscopy. Here, we have focused on rAAV5/5, 17 ,18 which appears to be a particularly good candidate for gene delivery to the respiratory tract because its receptor (2,3-N-linked sialic acid) is expressed on the apical surface of airway epithelial cells. 19, 20 In contrast, the more widely used rAAV2 requires access to the basolateral surface of airway epithelial cells where its main receptor, heparan sulfate proteoglycan, is most abundant. 21 We have investigated the efficiency of rAAV5/5-mediated transduction in the respiratory tract of the mouse, examining delivery to the epithelium lining the proximal airways of the nasal cavity, the conducting airways of the trachea, bronchi and bronchioles and the distal gas exchanging epithelium of the lung parenchyma. Whereas lung diseases such as cancer could benefit from acute transgene expression following gene transfer, chronic diseases such as CF may require persistent gene expression. We showed that rAAV5/5 vectors were substantially more potent than rAAV2/2 vectors and were able to direct dose-dependent increases in transgene expression that peaked 2-4 weeks post-administration and remained close to peak levels for at least 1 year. The rAAV5/5 efficiently transduced the olfactory sustentacular cells in the nasal epithelium, alveolar type II cells in the parenchyma, and, to a lesser extent, Clara cells in the conducting airways.
Results

Generation of high titer rAAV5/5 for in vivo studies
One limitation to the evaluation of novel viral vectors in vivo is the comparatively large quantities of pure, high-titer virus that are required. Advances in the field of rAAV2 production technology have eliminated the contamination risks associated with adenovirus (AdV) co-infection, 22, 23 and replaced CsCl density gradients with chromatography-based protocols. [24] [25] [26] [27] [28] Some of these advances were helpful in our production of rAAV5/5; transient triple-plasmid transfection avoided contamination with AdV and yielded high levels of virus in crude cell lysates. However, published affinity chromatography protocols for rAAV2/5 production 29 yielded insufficient rAAV5/5 virus for in vivo characterization (data not shown). Subsequently, we purified rAAV5/5 by CsCl gradient sedimentation, which provided final virus titers ranging from 7 Â 10 11 to 8 Â 10 12 DNAse-resistant genome copies (GC)/ml.
Characterization of rAAV5/5Lux transduction of nasal tissue
To investigate the transduction efficiency of rAAV5/5 in the respiratory tract, we first assessed the activity in the murine nose. Increasing doses of rAAV5/5Lux between 3 Â 10 9 and 3 Â 10 11 GC were perfused to the left nostril of BALB/c mice, and nasal tissue was harvested 4 weeks later. Increasing levels of luciferase activity were observed in the nasal tissue with increasing doses of virus (7.6271.75 RLU/mg protein for 3 Â 10 10 GC, P ¼ 0.0015; 43.84712.04 RLU/mg protein for 3 Â 10 11 GC, Po0.0001) (Figure 1a ). Luciferase activity from the lowest dose (3 Â 10 9 GC) was not significantly above the levels observed in naïve mice (P ¼ 0.51).
Mice were also treated with identical doses (GC) of rAAV2/2Lux, a rAAV2 vector containing an identical promoter and transgene expression cassette. Luciferase activity in nasal tissue of rAAV2/2Lux-treated mice was indistinguishable from naïve mice (Figure 1a ). Significant rAAV2/2Lux-mediated luciferase (3.687 0.78 RLU/mg protein, P ¼ 0.037 compared to naïve) was only noted when the delivered dose was increased to 1 Â 10 13 GC. To investigate the duration of gene expression achievable with rAAV5/5 in nasal tissue, groups of mice were perfused with 1 Â 10 11 GC rAAV5/5Lux and harvested at time points ranging between 2 days and 32 weeks post-administration (Figure 1b) . Peak expression was reached by day 14 (10.0772.36 RLU/mg protein) and was maintained at 4 and 8 weeks (11.6671.80 and 14.2772.54 RLU/mg protein). Luciferase activity declined gradually over the following months, but was still above naïve levels at 32 weeks (2.4670.82 RLU/mg protein; P ¼ 0.069).
rAAV5/5 transduces the lungs in a dose-dependent manner
We also investigated expression from rAAV5/5Lux in the lungs of BALB/c mice after delivery of between 3 Â 10 9 and 3 Â 10 11 GC virus to the lung. Significantly, increasing levels of luciferase activity were observed in the lungs with increasing doses of virus, with peak activity of 15.4573.23 RLU/mg protein for 3 Â 10 11 GC per mouse (Figure 2a) . Only mice treated with the highest dose of rAAV2/2Lux had luciferase activity significantly above background (Po0.0001) at levels (0.3770.08 RLU/mg protein) approximately 40-fold lower than an identical dose of rAAV5/5Lux. Increased luciferase activity was noted with rAAV2/2Lux when the delivered dose was further increased to 3 Â 10 12 GC Figure 1 Luciferase activity following delivery of rAAV2/2Lux and rAAV5/5Lux to the mouse nose. BALB/c mice were anaesthetized and 100 ml of virus were perfused to the left nostril. Expression from rAAV5/5 reaches peak levels by week 1 and persists for at least 12 months in the lungs When 1 Â 10 11 GC rAAV5/5Lux were delivered to the lungs, luciferase activity was detectable as early as 2 days after administration and reached a plateau by week 1 (21.1071.11 RLU/mg protein; Figure 2b ). These levels were maintained at peak for 8 weeks and tended to slowly decline over the following 24 weeks. By 32 weeks post-administration, luciferase levels were still B70% of the levels at 4 weeks. In a separate study, luciferase activity remained high even at 12 months post-administration (25.9172.61 RLU/mg protein), being still B50% of the levels at 3 months (54.3872.43 RLU/mg protein, Po0.0001) and B65% of the levels at 6 months (39.9372.57 RLU/mg protein, P ¼ 0.0001) (Figure 2c ).
Delivery of rAAV5/5Lux to the airways induces a systemic antibody response against the viral capsid
The observation that treatment with rAAV5/5Lux leads to long-term expression in the mouse respiratory tract suggests that no significant cellular immunity against the transduced cells has been induced. However, despite the prolonged reporter gene expression observed, it is apparent that gene expression levels tend to fall slowly towards background levels following delivery to both the nose (Figure 1b ) and the lung (Figures 2b and c) , and repeated administration of the vector would be required to maintain the expression levels achieved. We therefore investigated whether anti-AAV5-neutralizing antibody activity was present in the mice treated with 1 Â 10 11 GC rAAV5/5Lux, in the time-course experiments above. Crucially, neutralizing antibodies were detected as early as 1 week after delivery of the virus to the nose or lungs (Figure 3a) . For a more detailed analysis of the kinetics of the anti-AAV5 response, antibody titers (1/EC 50 ) were determined. Following delivery of rAAV5/5Lux to the nose, levels of anti-AAV5/5 antibody increased gradually over time up to the end of the experiment at week 32 ( Figure 3b) . Delivery of the virus to the lungs led to a more rapid anti-AAV5/5 antibody response, reaching peak levels within the first 2-3 months, then stabilizing throughout the 12-month time course (Figure 3b ). Together, these data suggest that repeated administration of rAAV5/5 to the murine airways is likely to be hindered by a long-lasting immune response.
Identification of cells transduced by rAAV5/5 in nasal epithelium
In order to identify the cell types transduced by rAAV5/ 5 in the nose, rAAV5/5EGFP was perfused to the left nostril of BALB/c mice, and after 4 weeks, nasal tissue was harvested for visualization of the enhanced green fluorescent protein (EGFP)-positive cells. Cells with detectable levels of EGFP fluorescence were readily apparent when nasal tissue was inspected immediately after harvesting (Figure 4a ). Subsequently, cryosections revealed that the vast majority of these EGFP-positive cells were sustentacular cells of the olfactory epithelium ( Figure 4b ). Importantly under the conditions used, no EGFP-positive cells could be detected in the respiratory epithelium of the nasal cavity (data not shown). Panels (e-h) in Figure 4 demonstrate differences in morphology between regions in the nose consisting mostly of olfactory epithelium (e and f) and regions that contain respiratory epithelium (g and h) (also refer to Mery et al.
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). 11 GC rAAV5/5EGFP (in 100 ml) were perfused to the left nostril. Nasal tissue was harvested at 4 weeks and wet tissue was photographed immediately through a fluorescence microscope (viewed at Â 20 original magnification) (a). The tissue was then processed for EGFP detection in cryosections (original image Â 40, bar is 5 mm) (b). EGFP detection is green, nuclei are stained with DAPI (blue). Equivalent photos from untreated control tissue in similar orientations are shown in panels (c) and (d). Sections from paraffinembedded nose tissue of untreated BALB/c mice, stained with hematoxylin and eosin, show typical regions of olfactory epithelium (OE) and respiratory epithelium (RE) (e: original image Â 5, bar is 100 mm, g: original image Â 10, bar is 100 mm, f and h: original image Â 40, of respective boxed area, bar is 20 mm), with the septum indicated as S. 
Discussion
Recombinant AAV gene transfer vectors have received much attention, as wild-type AAV causes no known human diseases and recombinant vectors retain no viral genes, thus minimizing the risk of cell-mediated host immune responses, as exemplified by adenoviral vectors. 31, 32 In particular, they have been evaluated in the respiratory tract where the majority of published studies have focused on rAAV2. Delivery of rAAV2 vectors to the rhesus monkey lung resulted in successful transduction of type II pneumocytes with no evidence of inflammation. 33, 34 The safe aerosolization of rAAV2 vector has also been confirmed in clinical trials to assess the potential for treatment of CF lung disease. 11, 35 However, the primary receptor for AAV2, heparan sulfate proteoglycan, is localized on the basolateral surface of airway epithelial cells 21 and therefore is not easily accessible from the apical (luminal) surface. This might explain the modest efficiency of rAAV2 when delivered directly to the lung compared with other rAAV serotypes. 19, 36 A variety of AAV serotypes have now been assessed for differences in gene transfer efficiency and tropism. 4, 14, 15 Here, we have focused on the rAAV5/5 vector, which is sufficiently divergent in its inverted terminal repeat (ITR) sequences and Rep protein that it cannot complement AAV2. 18 Recombinant AAV5/5 is an attractive option for gene transfer to the respiratory tract as it appears to use 2,3-N-linked sialic acid on the apical membrane as a receptor to transduce cells from the apical surface. 20 Aware of the increased purity and specific activity of chromatography-column purified rAAV2 compared with CsCl gradient-purified virus, we attempted to purify rAAV5 by affinity chromatography. However in our hands, this was not suitable for preparing virus at sufficiently high titers. We therefore established a protocol for the production of rAAV5/5, by transient human embryonic kidney (HEK) 293T cell transfection and CsCl gradient purification. Alternative methods have since been published which rely on cationexchange and anion-exchange chromatography, and may be valuable for further studies with rAAV5. 27, 37 Using our high-titer rAAV5/5 vectors, we have assessed the efficacy and duration of transgene expression in the mouse airways.
In our nasal studies, we chose perfusion as a delivery method to maximize contact between the virus solution and the respiratory epithelium of the nose. Perfusion of increasing doses of rAAV5/5 to the nasal cavity resulted in dose-dependent reporter gene expression, with little or no significant expression from the rAAV2/2 vector (Figure 1a ). This rAAV5/5-mediated expression peaked by day 14 and was maintained for 8 weeks, after which luciferase activity declined gradually over the following months (Figure 1b) . Dose-dependent transgene expression was also demonstrated in the mouse lung after instillation, again rAAV2/2 was outperformed by rAAV5/5 by approximately 40-fold (Figure 2a ). Peak expression from rAAV5/5 was maintained for up to 8 weeks (Figure 2b) . Expression began to decline after this time, but was still detectable 12 months after administration (Figure 2c) .
The persistent transgene expression observed here with rAAV5/5 and elsewhere with other AAV vectors 38, 39 may endure for the lifetime of the cell and is in contrast to the lack of persistence from non-viral vectors utilizing similar transgene expression cassettes. Several studies have shown that non-viral vectors (e.g. naked plasmid DNA or DNA/liposomes) often lead to transient gene expression when delivered to the mouse lung, despite the persistence of intact plasmid DNA. [40] [41] [42] Strong viral promoters such as the cytomegalovirus (CMV IE) promoter can become attenuated in the lung, resulting in silencing of transgene expression after only a few days. 41, 43 However, as we report here, CMVmediated reporter gene expression from rAAV5/5 is persistent under similar conditions. Intriguingly, when plasmid pAAV5/5Lux, containing the CMV-luciferase transgene cassette flanked by the AAV5 ITRs, was delivered to the mouse lung as naked plasmid DNA, luciferase expression was transient (data not shown). This suggests that the persistent luciferase activity from rAAV5/5Lux was not simply due to the presence of the viral ITRs in the transgene cassette. Persistent luciferase activity from rAAV5/5Lux might also be facilitated by the sequestration of the viral genome to a stable, transcriptionally active part of the nucleus. Alternatively, persistence of AAV expression could be due to the specific cell type transduced in the lung, for example, Type II pneumocytes with the capacity for division and self-renewal, compared with transgene expression in terminally differentiated cells. With regard to the persistence of viral genome DNA, there is a growing acceptance that rAAV genomes have lost the ability of wild-type AAV genomes to efficiently integrate in a sitespecific manner, into host cell chromosomal DNA after in vivo gene transfer. 44 Instead, it appears that in mouse and non-human primate tissues, rAAV genomes tend to form extrachromosomal concatemers [45] [46] [47] and that the presence of head-to-tail ITRs may be one mechanism for persistence of these concatemers. It would be interesting to investigate whether a similar profile of head-to-tail concatemers is present in rAAV5/5-treated respiratory tract samples.
To identify the cell type(s) transduced by rAAV5/5, we first delivered rAAV5/5EGFP to the nose. EGFPpositive cells were detected by direct visualization (Figure 3a ) and identified in cryosections as sustentacular cells of the olfactory epithelium (Figure 3b) . Importantly, no respiratory epithelial cells were scored positive for EGFP expression. This was unexpected as the AAV5 receptor has been reported to be located on the apical surface of respiratory cells. 18, 19 However, the distribution of 2,3-N-linked sialic acid in murine nasal epithelium as determined by lectin-binding assays is controversial. Studies by Foster et al. 48 and Yoon et al. 49 both suggested that the murine nasal respiratory epithelium was not labelled with Maackia amurensis agglutinin (MAA), which normally binds 2,3-N-linked sialic acid, while Ueno et al. 50 detected MAA binding on all nasal surfaces. So it remains feasible that a relative paucity of AAV5 receptor is responsible for the lack of EGFP-positive cells in the nasal respiratory epithelial cells. Importantly, the majority of the luciferase activity detected in the homogenized nasal epithelium (Figure 2 ) was probably due to transduction of sustentacular olfactory cells although it is also possible that expression in respiratory and other cell types was below the threshold for detection of EGFP or was obscured by autofluorescence. It remains encouraging that rAAV5/5 appears to be able to traffic into the nuclei of olfactory epithelial sustentacular cells.
Similarly, in the mouse lung, although we found a small proportion of respiratory epithelial cells that were positive for EGFP, more than 99% of the cells transduced with rAAV5/5EGFP were parenchymal cells ( Figure 5 ). This may appear to contradict previously published data showing that both conducting airway and parenchymal lung compartments were transduced to a similar extent. 19 In their study, Zabner et al. used rAAV5/5 expressing b-galactosidase from an rous sarcoma virus (RSV) promoter, which, in combination with several other minor experimental differences, could explain the apparently contrasting distribution. Indeed, we have observed that high levels of luciferase expression in the lung do not always correlate with detectable EGFP expression (data not shown), suggesting that the level of reporter gene expression per cell is an important factor for visualization of EGFP. Although this is a potential pitfall of studies involving EGFP, in our hands detection of EGFP has proved less prone to false positives than b-galactosidase staining. Nonetheless, the method used by Zabner et al. 19 for calculating the percentage of cells transduced in each compartment does not reflect the fact that there are many more parenchymal cells than conducting airway cells in the lungs. Presenting the data as absolute numbers per section or per square centimeter of whole section, rather than as a proportion of parenchymal or conducting airway cells, might bring their data more in line with our assessment of distribution of transduced cells. Similar experiments involving the delivery of rAAV2/5 vector to the mouse lung resulted in transgene expression in both conducting airway and alveolar cells, although the histochemical analysis was not quantitative. 39 Thus, the cell types transduced in mouse lungs may be more dependent on delivery and detection methods than a true reflection of the tropism of this virus. An important research objective for the use of rAAV5/5 in the lungs must be to identify cell types transduced by rAAV5/5 following aerosol delivery to large animal models using clinically relevant delivery methods.
A detailed understanding of the rAAV5/5 expression profile is crucial for the successful exploitation of these vectors in the lung. Persistent expression could be useful for long-term therapy of chronic lung diseases such as CF; and recent studies have shown that rAAV5/5 vectors can be used to correct CF chloride transport defects in airway epithelial cells grown in culture. 51 However, data presented here suggest that when rAAV5/5 is delivered to the mouse lung, it is unlikely to efficiently transduce airway cells which are the target for gene therapy of CF lung disease. In addition, animals demonstrating persistent luciferase expression for many months demonstrated a high level of anti-rAAV5 antibodies, including neutralizing antibodies, in serum (Figure 3) , suggesting that it might be difficult to repeatedly administer rAAV5/5 for treatment of chronic conditions. Whereas assays on sera do not directly demonstrate a local antibody response in the respiratory tract, preliminary studies suggest that this antibody response is sufficient to affect the efficiency of rAAV5 repeat administration in the mouse lung, and the implications of this immune response for the repeat administration of rAAV5/5 are being investigated further. Strategies to circumvent this inhibition include using alternative serotypes, although the choice of serotypes for a given application may be restricted by low tropism for the target cells or preexisting immunity in humans. Some rAAV serotypes have been shown to be immunologically distinct, such as rAAV2 versus rAAV6 52 or rAAV7 and 8 versus rAAV1, 2, 3, 4 and 6, 15 whereas others, such as rAAV2 and rAAV3,
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AAV5 airway gene transfer SG Sumner-Jones et al display some cross-neutralization. Another approach might be to modulate the immune response using immunosuppression 38, 53 or, with advances in the field of transplantation, 54 it may be possible to induce immunological tolerance.
Preferential transduction of parenchymal cells indicates that rAAV5/5 might be an appropriate gene transfer vector for treatment of diseases such as Acute Respiratory Distress Syndrome. 55, 56 Alternatively, this vector might be useful in the lung as a 'protein factory' for the production of therapeutic proteins not necessarily associated with the lung itself. Thus, efficient delivery to parenchymal cells that are closely associated with capillary blood vessels may be advantageous. This has been demonstrated in the lungs of mice using rAAV vectors to deliver erythropoietin and Factor IX into the systemic circulation. 39 The aim of this work was to provide further characterization of rAAV5/5 as a vector suitable for gene delivery to the lung. We have shown that rAAV5/5 vectors can result in long-term persistence of reporter gene expression in the murine nose and lung, with higher transduction efficiencies than rAAV2/2. Detection of EGFP expression in specific lung cell types revealed a preference for rAAV5/5 to transduce parenchymal Type II pneumocytes, with very few cells positive for EGFP expression observed in the respiratory epithelium of the nose and lung. Further elucidation of the mechanisms of virus tropism and improved gene delivery methods should allow these vectors to be successfully exploited for human therapy.
Materials and methods
Cells and plasmids
HEK 293T cells 57 and African green monkey kidney COS7 cells (ECACC) were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 4.5 g/l glucose (Invitrogen, Paisley, UK), supplemented with 10% heatinactivated fetal calf serum (FCS) (Sigma, Poole, UK).
The rAAV5 vector plasmid pAAV5/5Lux was constructed by replacing the RSV 3 0 LTR promoter and LacZ cDNA of pAAV5LacZ 18 with the 2.97 kb BglII-BamHI fragment from pCIKLux, 41 placing the CMV immediate early enhancer/promoter, recombinant intron and firefly luciferase cDNA between the ITRs of AAV5. The rAAV2 vector plasmid pAAV2/2Lux was constructed by replacing the CMV promoter, human growth hormone intron and LacZ cDNA of p2LacZ (Stratagene, Amsterdam, Netherlands) with the 2.97 kb BglII-BamHI fragment from pCIKLux. pAAV5/5EGFP was derived from pAAV5/5Lux by replacing the luciferase coding region with the EGFP coding region from pEGFP-N1 (Clontech, BD Bioscience, Cowley, UK). Plasmid stocks of p5RC (AAV5 helper plasmid), 18 pAAV5/5Lux, pAAV5/5EGFP and pAAV2/2Lux (vector plasmids) were prepared using QIAGEN EndoFree Plasmid Mega kits (QIAGEN, Crawley, UK). Endotoxin-free pAd12 (adenovirus helper plasmid) 18 was manufactured by Bayou Biolabs (Harahan, LA, USA).
Virus production
Recombinant AAV5 was produced by transient triple plasmid transfection of HEK 293T cells in a protocol modified from Drittanti et al. 58 Fifty 15-cm dishes of HEK 293T cells were transfected with 24 mg pAd12, 12 mg p5RC and 12 mg pAAV5/5-Lux or -EGFP per dish, using 25 kDa branched polyethylenimine (PEI, Sigma) in OPTIMEM (Invitrogen), at a ratio of 1.25 mg PEI per mg DNA (10:1 molar ratio of PEI nitrogens to DNA phosphates). After 24 h, the transfection medium was replaced with DMEM containing 10% FCS and antibiotics (100 U/ml penicillin, 100 mg/ml streptomycin, Gibco, Invitrogen, Paisley, UK) and the cells were cultured for a further 24 h. Virus was purified using CsCl density gradient ultracentrifugation. A cleared lysate was prepared using modifications to protocols published by Drittanti et al. 58 and Salvetti et al. 59 Cell pellets were dissolved in a total of 50 ml lysis buffer (50 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid (HEPES), 150 mM NaCl, 1 mM MgCl 2 , 1 mM CaCl 2 ), lysed by four freeze-thaw cycles and vortexed between each cycle. The lysates were centrifuged (1500 r.c.f., 15 min, 41C) and the supernatant was treated with Benzonase (Merck, VWR International Ltd, Lutterworth, UK) at a final concentration of 25 U/ml (15 min, 371C). Cell debris were eliminated by centrifugation (10 000 r.c.f., 20 min, 41C), an equal volume of ice-cold saturated ammonium sulfate was added to the decanted supernatant, and following thorough mixing, left on ice to precipitate for 1 h. Virus was pelleted by centrifugation (12 000 r.c.f., 30 min, 41C) and dissolved in 4 ml D-PBS (Dulbecco's phosphate-buffered saline (PBS) containing Ca 2+ and Mg
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; Invitrogen). The resulting lysate was laid over 3.3 ml CsCl (1.35 g/ml) underlaid with 3.3 ml CsCl (1.5 g/ml) and centrifuged (382 000 r.c.f., 15 h, 81C). Fractions of 30 drops (0.5 ml) were collected from the bottom of the centrifuge tube and screened by TaqMan real-time polymerase chain reaction (PCR) analysis (using pCIKLux-specific primers and probes as described by Gill et al.) 41 and/or measurement of refraction index (rI) of a 20 ml aliquot (Ceti Quartz refractometer; Meta Scientific, Windlesham, Surrey, UK). Fractions positive by TaqMan real-time PCR or with rI between 1.3738 and 1.3619 were pooled, added to 1.4 g/ml CsCl and centrifuged (382 000 r.c.f., 15 h, 81C). Fractions were collected and screened as before. Positive fractions were pooled and dialyzed in Slide-A-Lyzer dialysis cassettes (molecular weight cutoff 10 kDa) (Pierce, Perbio Science UK Ltd, Tattenhall, UK) against three 1 l changes of sterile 1 Â D-PBS for at least 3 h each at 41C. Virus was stored at À801C in 100-200 ml aliquots. The rAAV2/2Lux vector was produced and purified by the Vector Core at the Gene Therapy Program (University of Pennsylvania), using the pAAV2/2Lux genome construct.
Virus characterization
Final recombinant AAV titers (GC/ml) were always determined by TaqMan real-time PCR analysis of virus genomes (for both AAV5 and AAV2). Following digestion of viral preparations with DNAse I (Ambion, Austin, TX, USA), genomes were extracted with phenol: chloroform:isoamyl alcohol and precipitated. 59 Quantification was performed using a standard curve prepared by serial five-fold dilution of pAAV5/5Lux, from 3 Â 10 6 to 192 copies using pCIKLux-specific primers and probes as above. Function of the expression cassette was confirmed by detection of luciferase or EGFP 48 h after 
Animal studies
Female BALB/c mice aged 6-8 weeks were used throughout. Mice were housed in accordance with UK Home Office ethical and welfare guidelines, and fed on standard chow and water ad libitum. For nasal perfusion studies, mice were anaesthetized using Domitor (medetomidine hydrochloride, 0.1 mg/ml) (Pfizer Animal Health, Sandwich, Kent, UK) and Ketaset (ketamine hydrochloride, 7.6 mg/ml) (Fort Dodge Animal Health Ltd, Southampton, UK) mixed in sterile water, administered by intraperitoneal injection at a dose of 0.1 ml/10 g of animal. Mice were placed supine, head down, at an angle of approximately 451 on a heated pad. Virus was loaded into a 1 ml polypropylene syringe linked to a catheter (Portex polythene tubing, 2 mm inside diameter, 3 mm outside diameter; Jencons-PLC, Leighton-Buzzard, UK), stretched to a final outside diameter o0.5 mm. The catheter was placed to a depth of 2 mm, in the left nostril and a volume of 0.1 ml virus was perfused over 15 min (0.4 ml/h) using a syringe driver (Model U-74900-05, Cole-Parmer Instrument Co. Ltd, London, UK). Animal recovery was accelerated by administering 67 mg/ml Antisedan (atipamezole hydrochloride) (Pfizer Animal Health) diluted in 150 mM NaCl, by subcutaneous injection at a dose of 0.15 ml/10 g of animal. At the required times, mice were killed by cervical dislocation, and the nasal septum was collected with all attached tissue from the nasal cavity. Lung delivery and tissue harvesting were as described previously. 41 Preparation of cell and tissue extracts for luciferase assays COS7 cells were lysed in Reporter Lysis Buffer (RLB; Promega, Southampton, UK) with a single freeze-thaw cycle (À80/251C). For in vivo studies, lung tissues were minced with an Ultra-Turrax T8 tissue homogenizer (IKA Labortechnik, Staufen, Germany), and nose tissues were snipped with small spring scissors, in 200 ml RLB. Samples were frozen at À801C, thawed at 251C, centrifuged (16 000 r.c.f., 5 min, room temperature (RT)) and passed through a QIAshredder column (QIAGEN). Luciferase reporter activity was assayed in homogenates as described previously. 41 Naïve lung samples gave similar levels of background in luciferase assays to naïve nose samples, but contained 15-to 20-fold more protein, resulting in lower standardized values (see Figures 1 and 2 ).
Tissue processing for EGFP studies
For identification of cells transduced by rAAV5/5EGFP, animals were killed by cervical dislocation and dissected to reveal either nasal tissue or the lungs and trachea. Nasal tissue was fixed for 1 min in 4% paraformaldehyde. To enhance tissue morphology, lungs were intubated via the trachea and inflated with 4% paraformaldehyde at a pressure of 20 cm H 2 O for 1 h, then removed en bloc and fixed in 4% paraformaldehyde for a further 5 h. All tissues were subsequently incubated in 30% (w/v) sucrose in PBS overnight at 41C. Fixed tissue was embedded or inflated as appropriate in a 1:1 mixture of optimal cutting temperature (OCT) embedding matrix (Cellpath, Newtown, UK) and 30% sucrose, and semifrozen over liquid nitrogen. Sections were cut at 7 mm using a Leica CM3050 S cryostat (Leica Instruments GmbH, Nussloch, Germany) and mounted onto glass slides, dried overnight and rinsed in PBS for 10 min. The entire nasal septum was sampled in approximately 100 consecutive transverse sections. The trachea and individual lobes of the lung (apical, azygous, cardiac, diaphragmatic and left) were processed separately. Thirty non-consecutive cryosections were taken from each lobe and the trachea -a total of 180 sections per mouse. Sections were stored at À801C until required, for direct visualization and counting of EGFP-positive cells, or for cell type identification by counterstaining with antibodies. The average area of tissue sections was measured from scanned images of 10 cryosections for each lobe from inflated lungs and trachea, . Sections from paraffin-embedded tissue were used to illustrate the difference between olfactory and respiratory airway cells in the nose. Briefly, whole heads were fixed in 4% parafomaldehyde and decalcified in ethylenediaminetetraacetic acid (EDTA) (20% pH 7.4), the anterior section of the nose was then cut off and processed to paraffin. Microtome sections (7 mm) were placed onto glass slides and allowed to dry before removing the paraffin and staining with hematoxylin and eosin. Images were captured on a Micropublisher 5MP RT camera coupled to a Zeiss Axioskop microscope.
Immunofluorescent staining of cryosections
Sections were incubated with blocking buffer (10% FCS, 0.5% Triton X100 in PBS) for 10 min and the primary antibody was applied at 1:500 (rabbit anti-mouse SpB; Dako, Ely, UK) or 1:200 (rabbit anti-human urine protein, an alternative name for CCSP 60 (Dako)) dilution in blocking buffer, for 1 h in a humidified chamber at RT. Sections were rinsed three times in PBS and the biotinconjugated goat anti-rabbit secondary antibody was applied at 1:100 (for SpB) or 1:200 (for CCSP) dilution in blocking buffer, for 1 h, RT. Sections were rinsed as before. AlexaFluor 594-conjugated Streptavidin (Molecular Probes, Leiden, Netherlands) was diluted 1:1000 in blocking buffer and applied to sections for 30 min, RT. Sections were rinsed as before, washed in distilled water, allowed to air-dry, and mounted in fluorescent mounting medium (Dako) mixed with the fluorescent nuclear stain 4 0 ,6-diamidino-2-phenylindole (DAPI) (1:200). Slides were stored at 41C.
Immunofluorescence microscopy and image capture
Fluorescence images were captured using a Nikon Optiphot-2 epifluorescence microscope (Nikon UK, Kingston on Thames, UK) equipped with an FITC filter set (excitation 480/40 nm and emission 535/50 nm) for the detection of EGFP, a Texas Red filter set (excitation 560/40 nm and emission 630/60 nm) for the detection of AlexaFluor 594-labelled antibodies, and a UV filter set (excitation 360/40 nm and emission barrier filter 420 nm) for the detection of DAPI-labelled nuclei. Fluorescence signals detected in the red, green and blue channels were captured individually and composite RGB images AAV5 airway gene transfer SG Sumner-Jones et al generated using Openlab Version 4.0.3 image acquisition software (Improvision Ltd, Coventry, UK). Fluorescence images of freshly excised nasal tissue expressing GFP were captured directly using a Nikon Coolpix 4500 digital camera (Nikon) coupled to the eyepiece of the Optiphot-2 microscope.
Anti-AAV-neutralizing antibody assays
Serum from individual mice treated with rAAV5/5Lux was isolated at necropsy and aliquots pooled within the same treatment group. Pooled serum was diluted 20-fold in D-PBS and 20 ml were combined with 20 ml D-PBS containing 2 Â 10 9 GC rAAV5/5Lux. The virus/sera mixture was incubated for 1 h at RT and used to transduce 5 Â 10 4 COS7 cells. At 48 h post-transduction, cells were harvested and luciferase activity was determined as described above. Percentage inhibition of transduction was calculated by comparison to cells transduced with virus alone.
Detection of anti-AAV antibodies in pooled sera by enzyme-linked immunosorbent assay (ELISA)
Strip-well plates (Costar, VWR) were coated with 1 Â 10 9 GC rAAV5/5Lux in 50 ml D-PBS overnight at 371C. After blocking with 200 ml 1% FCS in PBS-T (0.1% Tween 20 in PBS), for 2 h at RT, serial dilutions (1:20-1:20 480 in PBS-T) of pooled sera were applied in duplicate in a final volume of 100 ml, overnight at +41C. Wells were washed three times with 200 ml PBS-T, and a 1:1000 dilution of horseradish peroxidase (HRP)-conjugated rabbit antimouse IgG, IgM, IgA (ab8518, AbCam, Cambridge, UK) in PBS-T was applied (100 ml per well), for 1 h at RT. Wells were washed as before, and 100 ml 3 0 ,3 0 ,5 0 ,5 0 -tetramethyl benzidine (TMB) substrate (Pierce) were applied per well, left for 10 min, before applying 100 ml 2 M sulfuric acid. Optical density (OD) was read at 450 nm using wells coated with virus and treated with secondary antibody only as blank. Using GraphPrism 4.0, the OD values were plotted as a function of the log dilution factor and fitted, using nonlinear regression, by the general dose-response equation:
where V min ¼ 0, V max ¼ maximum OD and B ¼ log dilution factor, and EC 50 ¼ dilution of sera at which OD is half of maximum. The titer is defined as the inverse dilution at which OD was half of maximum (i.e. 1/EC 50 ).
Statistical analyses
Luciferase activity data are expressed in RLU/mg protein, as the mean7standard error of the mean (s.e.m.). Statistical analysis was carried out on lognormalized data, using analysis of variance (ANOVA), with Fisher's PLSD post hoc correction.
